GLAUCOPHARM

glaucopharm-logo

GlaucoPharm is developing TG-46, a novel topical treatment for glaucoma. TG-46 is useful for the treatment of diseases modulated by the Pyrimidinergic receptor P2Y6, such lowering intraocular pressure (IOP) and there by Glaucoma. The P2Y6 receptor has been identified in Trabecular Meshwork cells (TM), an area of tissue in the eye that is responsible for draining the aqueous humor. TG-46 shows evidence of a novel mechanism of action, potential alternative to first line drugs, It binds tightl... y and selectively to P2Y6R. TG-46 reduces IOP by 45%, compared to the 25-35% of current drugs in the market. It is highly chemically and enzymatically stable (duration of action is higher than 3.5 hours). Its synthesis is facile and result in good yields. Preliminary data show that it does not exert several side-effects typical current drugs such as-effects on the cardiovascular systemโ€™ on the pupils or iris pigmentation.

#SimilarOrganizations #People #Website #More

GLAUCOPHARM

Industry:
Biotechnology Medical

Founded:
2013-01-01

Address:
Tel Aviv-yafo, Tel Aviv, Israel

Country:
Israel

Website Url:
http://www.abital.co.il

Total Employee:
1+

Status:
Closed

Email Addresses:
[email protected]

Technology used in webpage:
Domain Not Resolving


Similar Organizations

aerie-pharmaceuticals-logo

Aerie Pharmaceuticals

Aerie Pharmaceuticals is a clinical-stage pharmaceutical company developing products for the treatment of glaucoma.

Current Employees Featured

not_available_image

Orly Weinreb
Orly Weinreb CEO @ GlaucoPharm
CEO

not_available_image

Tali Fishman
Tali Fishman CTO @ GlaucoPharm
CTO

santiago-ini_image

Santiago Ini
Santiago Ini Founder @ GlaucoPharm
Founder

Founder


santiago-ini_image

Santiago Ini

Official Site Inspections

http://www.abital.co.il

Unable to get host informations!!!

Loading ...

More informations about "GlaucoPharm" on Search Engine